Get the Daily Brief
Latest Biotech News
Parse Biosciences and Codebreaker pair up to map variant effects in single cells
Parse Biosciences and Codebreaker Labs launched a collaboration to combine Codebreaker’s engineered variant libraries with Parse’s single‑cell transcriptomics platform to experimentally map how...
Cartography Biosciences clears IND for CBI‑1214 — T‑cell engager enters clinic
Cartography Biosciences received FDA clearance of an IND for CBI‑1214, a T‑cell engager targeting colorectal cancer, and announced plans to initiate a Phase I trial in Q1 next year. The program...
Singlera and Breakthrough launch preclinical study with Pitt — pancreatic early‑detection test
Singlera Genomics and Breakthrough Genomics partnered with the University of Pittsburgh to run a preclinical study validating the BT‑Reveal Early Pancreatic Cancer Test, which analyzes cell‑free...
Galux inks AI protein‑design pact with Boehringer Ingelheim — purposeful molecules next
South Korean AI protein‑design biotech Galux signed a research agreement with Boehringer Ingelheim to validate AI‑driven design of purpose‑specific protein molecules for therapeutic discovery. The...
BioMarin buys Amicus: $4.8B adds Pompe and Fabry franchises
BioMarin agreed to acquire Amicus Therapeutics in an all-cash transaction valued at about $4.8 billion, folding Amicus’ two approved rare-disease drugs for Pompe and Fabry diseases into BioMarin’s...
Cytokinetics wins FDA nod: Myqorzo clears obstructive hypertrophic cardiomyopathy
The FDA approved Cytokinetics’ Myqorzo, the company’s first U.S. drug, for obstructive hypertrophic cardiomyopathy, delivering a long‑sought commercial milestone after nearly three decades of...
ADC safety and target momentum: Daiichi holds trial; B7‑H3 gains interest
Daiichi Sankyo and Merck’s phase III program testing an antibody‑drug conjugate (I‑DXd/ifinatamab deruxtecan) in small‑cell lung cancer was placed on partial clinical hold after a...
Trump administration restrictions freeze NIH operations: $1.5B in grants affected
The U.S. administration imposed restrictions across NIH operations in early 2025 that halted grant reviews, external communications, travel and hiring, and proposed a 15% cap on indirect costs on...
Epigenovo commercializes scFFPE‑ATAC: single‑cell chromatin for clinical samples
Swedish spinout Epigenovo is developing a high‑throughput single‑cell chromatin accessibility assay compatible with formalin‑fixed, paraffin‑embedded (FFPE) tissue—scFFPE‑ATAC—and is raising funds...
Parse and Codebreaker link variant libraries to single‑cell readouts — experimental genomics scale
Parse Biosciences and Codebreaker Labs entered a collaboration to combine engineered variant libraries with Parse’s single‑cell transcriptomics platform to map how genetic variants affect cell...
Singlera, Breakthrough join U Pitt to test early pancreatic‑cancer methylation assay
Singlera Genomics and Breakthrough Genomics partnered with the University of Pittsburgh to run a preclinical study of the BT‑Reveal early pancreatic cancer test, which analyzes cfDNA methylation...
Galux and Boehringer agree AI protein‑design research pact
South Korean AI‑driven protein design company Galux signed a research agreement with Boehringer Ingelheim to evaluate AI methods for designing purpose‑specific protein molecules. The collaboration...
JAX merges with NYSCF: unified nonprofit to scale genetics and stem‑cell translation
The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and celebrated the launch of a unified organization that combines JAX’s strengths in mouse genetics with...
Nonprofit rescues abandoned gene therapy — tests whether model can scale
A nonprofit organization has successfully brought an abandoned rare‑disease gene therapy to market, raising questions about whether the model can scale to other neglected or uncommercialized...
BioMarin to buy Amicus: $4.8B deal adds Fabry and Pompe drugs
BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion, bringing two marketed rare‑disease therapies and a late‑stage pipeline asset into its portfolio. The boards of both companies...
Phase III paused: ADC trial halted after deaths
Sponsors halted recruitment and enrollment in a phase III study of the antibody‑drug conjugate (ADC) ifinatamab deruxtecan after a higher‑than‑anticipated incidence of fatal interstitial lung...
FDA clears Cytokinetics’ heart drug – company secures first U.S. approval
The U.S. Food and Drug Administration approved Cytokinetics’ Myqorzo, marking the company’s first U.S. drug approval after a multi‑decade effort. The approval targets obstructive hypertrophic...
Single‑cell translation ramps: FFPE chromatin kit and variant–cell mapping pact
Two announcements signaled expansion of single‑cell capabilities toward clinical and functional genomics. Swedish spinout Epigenovo unveiled its scFFPE‑ATAC assay to profile chromatin...
Galux, Boehringer test AI protein design – partnership for purpose‑built molecules
Galux signed a research agreement with Boehringer Ingelheim to explore AI‑driven protein design for therapeutic applications. The collaboration will evaluate whether generative and predictive...
White House seals nine drug‑pricing pacts: largest batch yet
The White House finalized agreements with nine major drugmakers to lower Medicaid prices to levels paid by peer nations as part of a most‑favored‑nation (MFN) strategy. Companies named in the...